Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...

"We are thrilled to share the pivotal Phase 3 study results comparing our biosimilar bUstekinumab with the reference product ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.